-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Probe into Thales defence group looking at Indonesian contract
-
US to cancel flights as longest govt shutdown drags on
-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
-
IPL champions Bengaluru could be sold for 'as much as $2 billion'
-
Budget impasse threatens Belgium's ruling coalition
-
New Zealand ex-top cop admits to having material showing child abuse, bestiality
-
BoE set for finely balanced pre-budget rate call
-
Australian kingpin obtains shorter sentence over drug charge
-
Weatherald's unenviable Ashes task: fill giant hole at top left by Warner
-
Ovechkin first to score 900 NHL goals as Capitals beat Blues
-
On Mexico City's streets, vendors fight to make it to World Cup
-
Asian markets bounce from selloff as US jobs beat forecasts
-
Philippine death toll tops 140 as typhoon heads towards Vietnam
-
Kyrgios targets 'miracle' Australian Open return after knee improves
-
'AI president': Trump deepfakes glorify himself, trash rivals
-
Belgium probes drone sightings after flights halted overnight
-
Five things to know about 'forest COP' host city Belem
-
World leaders to rally climate fight ahead of Amazon summit
-
Engine fell off US cargo plane before deadly crash: officials
-
Mexican leader calls for tougher sexual harassment laws after attack
-
Meghan Markle set for big screen return: reports
-
Japan deploys troops after wave of deadly bear attacks
-
Diageo PLC Issues Fiscal 26 Q1 Trading Statement
-
NV Gold Announces Closing of First Tranche of Private Placement
-
FIFA announce new peace prize to be awarded at World Cup draw in Washington
-
Australia's Cummins hints at return for second Ashes Test
-
Boeing settles with one plaintiff in 737 MAX crash trial
-
Man City win as Inter stay perfect, Barca held in Champions League
-
French superstar DJ Snake wants new album to 'build bridges'
-
Barca rescue draw at Club Brugge in six-goal thriller
-
Foden hits top form as Man City thrash Dortmund
-
NBA officials brief Congress committee over gambling probe
-
Inter beat Kairat Almaty to maintain Champions League perfection
-
Newcastle sink Bilbao to extend Champions League winning run
-
Wall Street stocks rebound after positive jobs data
-
LPGA, European tour partner with Saudis for new Vegas event
-
Eyes turn to space to feed power-hungry data centers
-
Jazz lose Kessler for season with shoulder injury
-
League scoring leader Messi among MLS Best XI squad
-
MLS bans Suarez for Miami's winner-take-all playoff match
World-first IVF trial reduces risk of babies inheriting diseases
Eight healthy babies have been born in the UK using a new IVF technique that successfully reduced their risk of inheriting genetic diseases from their mothers, the results of a world-first trial said Wednesday.
The findings were hailed as a breakthrough which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children.
One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting.
In 2015, Britain became the first country to approve an in-vitro fertilisation (IVF) technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor -- along with the mother's egg and father's sperm.
Some have called the result of this process "three-parent babies", though researchers have pushed back at this term because only roughly 0.1 percent of the newborn's DNA comes from the donor.
The results of the much-awaited UK trial were published in several papers in the New England Journal of Medicine.
- 'Important reproductive option' -
Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under six months to over two years old.
The amount of mutated mitochondrial DNA -- which causes disease -- was reduced by 95-100 percent in six of the babies, according to the research.
For the other two newborns, the amount fell by 77-88 percent, which is below the range that causes disease.
This indicates the technique was "effective in reducing transmission" of diseases between mother and child, one of the studies said.
The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said.
Their health will be followed up over the coming years to see if problems arise.
Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed the "breakthrough".
The new technique offers a "very important reproductive option" for families affected by "devastating" mitochondrial diseases, he added.
- Ethical review -
Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France.
Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered "designer babies".
An ethical review carried out by the UK's independent Nuffield Council on Bioethics was "instrumental" in conducting the new research, the council's director Danielle Hamm said Wednesday.
Peter Thompson, head of the UK's Human Fertilisation and Embryology Authority which approved the procedure, said only people with a "very high risk" of passing on a mitochondrial disease would be eligible for the treatment.
Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine.
French mitochondrial disease specialist Julie Stefann told AFP that "it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious".
"In the context of infertility, it has not been proven," she added.
Oxford University reproductive genetics expert Dagan Wells observed that "some scientists will be a little disappointed that so much time and effort has, so far, only led to the birth of eight children".
Among the children being closely monitored are three that showed some signs of what is known as "reversal", which is still little understood.
It is "a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased," he explained.
J.Oliveira--AMWN